Ladarixin

Research use only, not for human use.

A novel allosteric, noncompetitive dual CXCR1/2 inhibitor that inhibits human polymorphonuclear leukocyte (PMN) migration to CXCL8 in vitro with IC50 of 0.7 nM.

A novel allosteric, noncompetitive dual CXCR1/2 inhibitor that inhibits human polymorphonuclear leukocyte (PMN) migration to CXCL8 in vitro with IC50 of 0.7 nM; prevents PMN infiltration and tissue damage in several models of IR injury in vivo; abrogates motility and induces apoptosis in cultured cutaneous and uveal melanoma cells and xenografts; also prevents inflammation-mediated damage in MLD-STZ, prevents and reverses diabetes in NOD mice.Diabetes Phase 2 Clinical.

——

Animal Model:Mice (cigarette smoke-induced exacerbation of Influenza-A infection model)Dosage:10 mg/kg Administration:P.o. once a day at days 2, 3 and 4 post-infection Result:Significantly attenuated the exacerbation in lethality and respiratory changes noted in CSFlu group.

DF 2156 | DF 2156A

GPCR/G Protein

Chemokine Receptor

Chemokine Receptor

Metabolic Disease

Diabetes

849776-05-2

375.333

C11H12F3NO6S2

>98% (HPLC)

In Vitro:?DMSO : 100 mg/mL (266.43 mM)

CC(C1=CC=C(C=C1)OS(=O)(=O)C(F)(F)F)C(=O)NS(=O)(=O)C

4-((2R)-1-Oxo-1-(methanesulfonamido)propan-2-yl)phenyl trifluoromethanesulfonate

(-20℃)

With Ice Pack

≥ 2 years